G-treeBNT Co.
GtreeBNT Co., Ltd. (www.gtreebnt.com) is a clinical development pharmaceutical company listed on the Korean stock market that aims to acquire the rights to early clinical stage pipeline pharmaceuticals targeted at diseases with unmet needs, including rare diseases. GtreeBNT plans to rapidly develop the pharmaceuticals through additional studies, formulation development, and clinical trials for commercialization. Currently, its U.S. subsidiary, ReGenTree, LLC (www.regentreellc.com), is conducting a second Phase 3 clinical trial (ARISE-2) for dry eye syndrome (DES) and a Phase 3 trial (SEER-1) for the orphan ocular disease neurotrophic keratopathy (NK) using RGN-259 eye drops. In addition, GtreeBNT is conducting a Phase 1b trial for the orphan disease glioblastoma multiforme (GBM) using OKN-007 in U.S.